|Table of Contents|

Clinicopathological characteristics of renal cell carcinoma complicated by maintenance hemodialysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 05
Page:
885-889
Research Field:
Publishing date:

Info

Title:
Clinicopathological characteristics of renal cell carcinoma complicated by maintenance hemodialysis
Author(s):
ZHOU Jie; BAO Yougen; ZHU Zunwei; HUANG Haipeng; ZHU Xinshen; FU Donghui; JIA Linghua; MAO Yunyi; WANG Jingen; CHEN Jie
Department of Urology,Jiangxi Provincial People's Hospital/the First Affiliated Hospital of Nanchang Medical College,Jiangxi Nanchang 330006,China.
Keywords:
renal cell carcinoma（RCC）; maintenance hemodialysis; clinicopathologic features; prognosis
PACS:
R737.11
DOI:
10.3969/j.issn.1672-4992.2023.05.019
Abstract:
Objective：To explore the clinicopathological characteristics and prognosis in maintenance hemodialysis(MHD) patients with renal cell carcinoma(RCC).Methods:We retrospectively analyzed the clinicopathological data of 10 patients with renal cell carcinoma complicated by MHD admitted to our hospital from January 2013 to January 2020,and compared them with RCC patients with normal renal function during the same period.Results:There were 6 males and 4 females,with an average age of 49.4(31~63) years old.The mean duration of hemodialysis before a diagnosis of RCC was 49.6(19~62) months.In 3 patients,RCC was accompanied by acquired cystic kidney disease(ACKD).Only 1 patient presented with gross hematuria,and the other 9 patients were asymptomatic.Tumors were unilateral and solitary.The mean largest dimension of the tumor was 3.9(1.2~5.4) cm.Only 1 patient with hematuria had T3aN0M0 disease,the remaining 9 patients had T1N0M0.All the patients underwent retroperitoneal laparoscopic radical nephrectomy.Postoperative pathology showed RCC in all 10 patients.Clear cell carcinoma occurred in 9 patients(90%),and papillary RCC in 1 patient(10%).Compared to RCC patients with normal renal function,MHD-complicated RCC patients were younger,had smaller tumors,and had lower WHO/ISUP grading(P＜0.05).10 patients were followed up for 26~104 months,with a median follow-up of 64.7(26~104) months.All the patients survived,and no recurrence or metastasis was found.Conclusion:RCC arising in MHD patients exhibit many favorable clinical and pathologic features,and a good prognosis can be achieved after active surgical treatment.Patients undergoing MHD need to be alert to the risk of concurrent RCC and need to be screened regularly as most patients have no clinical symptoms.

References:

[1] 何丽娜,楼伊云,何金灿,等.慢性肾脏病患者肿瘤发病情况和相关危险因素［J］.中华肾脏病杂志,2020,36(06):487-491. HE LN,LOU YY,HE JC,et al.Tumor incidence and related risk factors in patients with chronic kidney disease［J］.Chinese Journal of Nephrology,2020,36(06):487-491.
[2] 李修明,宋殿宾,刘慧,等.血液透析患者合并尿路上皮癌12例临床分析［J］.现代肿瘤医学,2021,29(10):1732-1734. LI XM,SONG DB,LIU H,et al.Clinical analysis of 12 patients with urothelial carcinoma complicated by hemodialysis［J］.Modern Oncology,2021,29(10):1732-1734.
[3] ISHIHARA H,FUKUDA H,TACHIBANA H,et al.Outcome of advanced renal cell carcinoma arising in end-stage renal disease:comparison with sporadic renal cell carcinoma［J］.Clin Exp Nephrol,2021,25(6):674-682.
[4] 周杰,陈捷,范思斯,等.终末期肾病合并肾恶性肿瘤的临床特点及预后［J］.中华泌尿外科杂志,2021,42(11):862-863. ZHOU J,CHEN J,FAN SS,et al.Clinical characteristics and prognosis of malignant renal tumor in end-stage renal disease patients［J］.Chinese Journal of Urology,2021,42(11):862-863.
[5] TSUZUKI T,IWATA H,MURASE Y,et al.Renal tumors in end-stage renal disease:A comprehensive review［J］.Int J Urol,2018,25(9):780-786.
[6] EL-ZAATARI ZM,TRUONG LD.Renal cell carcinoma in end-stage renal disease:A review and update［J］.Biomedicines,2022,10(3):657.
[7] NOUH M A,KURODA N,YAMASHITA M,et al.Renal cell carcinoma in patients with end-stage renal disease:relationship between histological type and duration of dialysis［J］.BJU Int,2010,105(5):620-627.
[8] JOHNSON TA,MAEKAWA S,FUJITA M,et al.Genomic features of renal cell carcinoma developed during end-stage renal disease and dialysis［J］.Hum Mol Genet,2022,32(2):290-303.
[9] HURST FP,JINDAL RM,FLETCHER JJ,et al.Incidence,predictors and associated outcomes of renal cell carcinoma in long-term dialysis patients［J］.Urology,2011,77(6):1271-1276.
[10] CARNAHAN MB,KUNZELMAN J,KAWASHIMA A,et al.Acquired cystic disease subtype renal cell carcinoma(ACD-RCC):prevalence and imaging features at a single institution［J］.Abdom Radiol(NY),2022,47(8):2858-2866.
[11] 刘慧洁.维持血液透析患者肿瘤发生及其相关因素的探讨［J］.中华肿瘤防治杂志,2018,25(S2):85,87. LIU HJ.Tumor occurrence and its related factors in maintenance hemodialysis patients［J］.Chinese Journal of Cancer Prevention and Treatment,2018,25(S2):85,87.
[12] BUTLER AM,OLSHAN AF,KSHIRSAGAR AV,et al.Cancer incidence among US medicare ESRD patients receiving hemodialysis,1996-2009［J］.Am J Kidney Dis,2015,65(5):763-772.
[13] ROSNER MH.Cancer screening in patients undergoing maintenance dialysis:Who,what and when［J］.Am J Kidney Dis,2020,76(4):558-566.
[14] HOLLEY JL.Screening,diagnosis,and treatment of cancer in long-term dialysis patients［J］.Clin J Am Soc Nephrol,2007,2(3):604-610.
[15] JAMES LJ,WONG G,TONG A,et al.Patient preferences for cancer screening in chronic kidney disease:a best-worst scaling survey［J］.Nephrol Dial Transplant,2021，37(12):2449-2456.
[16] NEUZILLET Y,TILLOU X,MATHIEU R,et al.Renal cell carcinoma(RCC) in patients with end-stage renal disease exhibits many favourable clinical,pathologic,and outcome features compared with RCC in the general population［J］.Eur Urol,2011,60(2):366-373.
[17] BREDA A,LUCARELLI G,RODRIGUEZ-FABA O,et al.Clinical and pathological outcomes of renal cell carcinoma(RCC) in native kidneys of patients with end-stage renal disease:a long-term comparative retrospective study with RCC diagnosed in the general population［J］.World J Urol,2015,33(1):1-7.
[18] 周杰,朱遵伟,曾涛,等.维持性血液透析患者后腹腔镜肾癌根治术的安全性［J］.中国微创外科杂志,2020,20(03):274-277. ZHOU J,ZHU ZW,ZENG T,et al.On safety of retroperitoneoscopy in maintenance hemodialysis patients with renal cell carcinoma［J］.Chinese Journal of Minimally Invasive Surgery,2020,20(03):274-277.
[19] FINELLI A,CHEUNG DC,AL-MATAR A,et al.Small renal mass surveillance:Histology-specific growth rates in a biopsy-characterized cohort［J］.Eur Urol,2020,78(3):460-467.
[20] 张海宝,朱国栋.小肾癌转移的诊治研究进展［J］.现代泌尿外科杂志,2021,26(1):88-90,92. ZHANG HB,ZHU GD.Advances in the diagnosis and treatment of small renal cancer metastasis［J］.Journal of Modern Urology,2021,26(1):88-90,92.
[21] WARREN AY,HARRISON D.WHO/ISUP classification,grading and pathological staging of renal cell carcinoma:standards and controversies［J］.World J Urol,2018,36(12):1913-1926.
[22] KONDO T,SASA N,YAMADA H,et al.Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients:Central pathology results according to the 2016 WHO classification in a multi-institutional study［J］.Pathol Int,2018,68(10):543-549.
[23] 张伟,徐丽丽,于文娟,等.获得性囊性肾病相关性肾细胞癌临床病理学观察［J］.中华病理学杂志,2018,47(5):366-371. ZHANG W,XU LL,YU WJ,et al.Acquired cystic kidney disease-associated renal cell carcinoma:a clinicopathologic study of three cases［J］.Chinese Journal of Pathology,2018,47(5):366-371.
[24] ROBILAV,KRAFT AO,SMITH SC.New entities,new technologies,new findings:A review of the cytologic features of recently established subtypes of renal cell carcinoma［J］.Cancer Cytopathol,2019,127(2):79-97.

Memo

Memo:
江西省卫健委普通科研课题（编号：20203076）
Last Update: 2023-01-31